TY  - JOUR
AU  - Ochoa, Maria C
AU  - Perez-Ruiz, Elisabeth
AU  - Minute, Luna
AU  - Oñate, Carmen
AU  - Perez, Guiomar
AU  - Rodriguez, Inmaculada
AU  - Zabaleta, Aintzane
AU  - Alignani, Diego
AU  - Fernandez-Sendin, Myriam
AU  - Lopez, Ascension
AU  - Muntasell, Aura
AU  - Sanmamed, Miguel F
AU  - Paiva, Bruno
AU  - Lopez-Botet, Miguel
AU  - Berraondo, Pedro
AU  - Melero, Ignacio
PY  - 2019
DO  - 10.1080/2162402X.2019.1599636
SN  - 2162-4011
UR  - https://hdl.handle.net/10668/26683
T2  - Oncoimmunology
AB  - Daratumumab is an anti-CD38 fully human IgG1 mAb approved for multiple myeloma treatment. One of the proposed mechanisms of action is the induction of antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells. NK cells acquire surface CD137...
LA  - en
KW  - ADCC
KW  - CD137
KW  - NK cells
KW  - daratumumab
KW  - multiple myeloma
TI  - Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells.
TY  - research article
VL  - 8
ER  -